Effects of moxonidine on sympathetic nervous system activity: An update on metabolism, cardio, and other target-organ protection | Zendy

C V Savopoulos | Zendy; EleniF Karlafti | Zendy; Apostolos Hatzitolios | Zendy; AnastasiosF Karlaftis | Zendy; MariaS Baltatzi | Zendy; George Koliakos | Zendy

Open Access

Effects of moxonidine on sympathetic nervous system activity: An update on metabolism, cardio, and other target-organ protection

Author(s) -

C V Savopoulos,

EleniF Karlafti,

Apostolos Hatzitolios,

AnastasiosF Karlaftis,

MariaS Baltatzi,

George Koliakos

Publication year - 2013

Publication title -

journal of pharmacy and bioallied sciences

Language(s) - English

Resource type - Journals

eISSN - 0976-4879

pISSN - 0975-7406

DOI - 10.4103/0975-7406.120067

Subject(s) - moxonidine , imidazoline receptor , medicine , pharmacology , sympathetic nervous system , agonist , adverse effect , sympathetic activity , blood pressure , receptor , heart rate

Moxonidine is the newest, second-generation, centrally acting antihypertensive agent. It has selective agonist activity at imidazoline I1 receptors and less adverse effects than the other centrally acting drugs. This fact authorizes the frequent use of moxonidine in clinical practice, as monotherapy or in combination with other antihypertensive agents. Also, moxonidine has beneficial effects in obese and metabolic syndrome and in target-organs, such as heart and kidneys.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research